Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

The short interest in Hims & Hers Health (NYSE:HIMS) has approached critical levels, financial data provider S3 Partners said ...

Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...

Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

As more than 100 million Americans live with obesity, Hims & Hers is aggressively positioning itself at the intersection of telehealth and chronic disease management. This partnership enables ...

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.85, a high estimate of $68.00, ...

Overall, though, we'd argue that HIMS's stock is in a great position to sell puts on. At this price, the options pay a ...